Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial.

Published

Journal Article

OBJECTIVE: To investigate the methylphenidate (MPH) response rate among childhood survivors of acute lymphoblastic leukemia (ALL) and brain tumors (BTs) and to identify predictors of positive MPH response. METHODS: Cancer survivors (N = 106; BT = 51 and ALL = 55) identified as having attention deficits and learning problems participated in a 3-week, double-blind, crossover trial consisting of placebo, low-dose MPH (0.3 mg/kg), and moderate-dose MPH (0.6 mg/kg). Weekly teacher and parent reports on the Conners' Rating Scales were gathered. RESULTS: Following moderate MPH dose, 45.28% of the sample was classified as responders. Findings revealed that more problems endorsed prior to the medication trial on parent and teacher ratings were predictive of positive medication response (p < .05). CONCLUSIONS: MPH significantly reduces attention problems in a subset of childhood cancer survivors. Parent and teacher ratings may assist in identifying children most likely to respond to MPH so prescribing may be optimally targeted.

Full Text

Duke Authors

Cited Authors

  • Conklin, HM; Helton, S; Ashford, J; Mulhern, RK; Reddick, WE; Brown, R; Bonner, M; Jasper, BW; Wu, S; Xiong, X; Khan, RB

Published Date

  • March 2010

Published In

Volume / Issue

  • 35 / 2

Start / End Page

  • 144 - 155

PubMed ID

  • 19465537

Pubmed Central ID

  • 19465537

Electronic International Standard Serial Number (EISSN)

  • 1465-735X

Digital Object Identifier (DOI)

  • 10.1093/jpepsy/jsp044

Language

  • eng

Conference Location

  • United States